Compare Enveric Biosciences Inc (ENVB) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Payoneer Global Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Payoneer Global Inc trades at $7.19 (market cap $2.43B). The key difference: Payoneer Global Inc is far larger — about 363.2× Enveric Biosciences Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Payoneer Global Inc for 61 Days on average.
| ENVB | PAYO | |
|---|---|---|
Market Cap | $6.69M | $2.43B |
Volume | 41,141 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $10.80 | $7.18 |
52-Week Low | $1.27 | $4.27 |
Typical Hold Time | 14 Days | 61 Days |
Enterprise Value | -$1.60M | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Payoneer (PAYO) trades at $7.16, up 0.14% on the day, with a bullish technical signal from moving averages and a mixed earnings history including a Q2 2026 miss. Revenue grew to $821.16M in 2025, but net income declined to $73.19M, compressing margins. The company renewed its partnership with Etsy through 2029 and faces ongoing legal scrutiny regarding its proposed acquisition by Nuvei.
The outlook is cautious; while analyst consensus is 60% buy-rated and cash flow trends are positive, risks include earnings volatility, acquisition uncertainty, and competitive pressures. Investors should weigh strong institutional interest against execution challenges and margin pressures for medium-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
